John R Lozada, Andrew Elliott, Mark G Evans, James Wacker, Kathleen M Storey, Emily A Egusa, Nicholas A Zorko, Akhilesh Kumar, Anthony Crymes, Elisabeth I Heath, Benedito A Carneiro, Heloisa P Soares, Frank Cichocki, Jeffrey S Miller, Emil Lou, Himisha Beltran, Emmanuel S Antonarakis, Charles J Ryan, Justin H Hwang
{"title":"Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.","authors":"John R Lozada, Andrew Elliott, Mark G Evans, James Wacker, Kathleen M Storey, Emily A Egusa, Nicholas A Zorko, Akhilesh Kumar, Anthony Crymes, Elisabeth I Heath, Benedito A Carneiro, Heloisa P Soares, Frank Cichocki, Jeffrey S Miller, Emil Lou, Himisha Beltran, Emmanuel S Antonarakis, Charles J Ryan, Justin H Hwang","doi":"10.1158/2767-9764.CRC-24-0501","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"318-326"},"PeriodicalIF":2.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827001/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0501","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Significance: DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
